Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart rhythm rematch: does extra scarring boost ablation success?

NCT ID NCT06988202

Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two ways to repeat a heart ablation for people with persistent atrial fibrillation (AF) whose first ablation didn't work. The standard repeat method isolates the pulmonary veins; the experimental method also treats the left atrial posterior wall. Researchers will track how symptoms change over time in 630 participants to see which approach leads to better heart rhythm control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation procedure (pulmonary vein isolation with or without left atrial posterior wall isolation)
What this could lead to
If adding left atrial posterior wall isolation works better, it could offer a more effective repeat treatment for people with persistent atrial fibrillation, reducing symptoms and the need for further procedures.
What could go wrong
This is a mid-stage comparative study, not a final proof of cure. The added step may not improve outcomes and could carry extra risks like damage to nearby structures. Results may not apply to all AF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥ 18 years on date of consent * One prior PVI ablation procedure \> 3 months prior for persistent AF * Recurrent paroxysmal or persistent symptomatic AF confirmed on ECG despite prior PVI * Eligible for repeat ablation procedure * Willingness to comply with all post-procedural follow-up requirements and to sign informed consent Exclusion Criteria * Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus) * Prior ablation that included non-PVI LA ablation, or more than one prior PVI ablation procedure for persistent AF * Prior surgical ablation for AF * Contraindication to systematic anticoagulation * LA diameter on echocardiogram \> 6.0 cms * LV ejection fraction \< 35% * NYHA class III-IV congestive heart failure * Acute coronary syndrome or coronary artery bypass surgery or percutaneous coronary intervention (balloon and/or stent angioplasty) within 3 calendar months prior to consent date * Enzyme-positive myocardial infarction within the past 3 calendar months prior to consent * Severe aortic or mitral valvular heart disease eligible for percutaneous or surgical repair/replacement procedures * Prior valve replacement with mechanical prosthesis * Angiographic evidence of coronary disease that requires coronary revascularization and with likelihood of undergoing a CABG or PCI in the next 3 calendar months following consent date * Stroke within 3 calendar months prior to consent date * Any medical condition likely to limit survival to \< 1 year * Renal failure requiring dialysis at time of consent * Pregnancy * History of non-compliance to medical therapy * Participation in other clinical trials (observational/lead registries are allowed) without approval from the CCRC * Inability or unwillingness to provide informed consent * Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult * Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Rochester Clinical Cardiovascular Research Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.